These targets are important in maintaining mutant KRAS lung adenocarcinomas [34, 35] suggesting that relieving some cellular anti-apoptosis restraints with SMAC mimetics may be effective in concert with some of these therapies. Here, KRAS is linked to lung adenocarcinoma.